key: cord-0972540-3agfn4bw
authors: Bozorgmehr, Kayvan; Jahn, Rosa
title: Obligations in a global health emergency
date: 2021-12-02
journal: Lancet
DOI: 10.1016/s0140-6736(21)02337-0
sha: 38f4775df7dcbbb085aec320f9a3a4e4f7a0aa89
doc_id: 972540
cord_uid: 3agfn4bw

nan

Ezekiel Emanuel and colleagues note in their Viewpoint 1 that everyone agrees that business as usual is unacceptable in a pandemic. Yet their focus on sustainability for industry implicitly supports the status quo.

The status quo allows patents and other intellectual property (IP) barriers to impede access to medical tools. 2 IP-backed monopolies have left countries such as Brazil paying double their total 2021 routine immunisation programmes budget to Pfizer for COVID-19 vaccines, jeopardising the sustainability of the public health system by perpetuating reliance on corporate goodwill for access to lifesaving vaccines and therapeutics. 3 Some voluntary measures could improve access to medicines. For example, the new WHO COVID-19 mRNA Vaccine Technology Transfer Hub is an opportunity for companies to share IP and know-how to help scale up and diversify production, not in years but in months. 4 However, no mRNA vaccine developers have joined this initiative yet.

Contrary to the Ezekiel Emanuel and colleagues' scepticism, more than 100 countries, many of which are low-income or middle-income countries, endorse waiving certain COVID-19 IP protections to enable additional legal tools to overcome IP monopolies. 2 This strategy could help change the status quo and would not undermine innovation. Patents are not the driving force for medical innovation, 5 and public funding contributed considerably to the development of COVID-19 vaccines.

With a world locked down and millions of excess deaths, what will it take for us to improve the IP system? How can we build a more equitable, sustainable, and accountable medical innovation system that serves everyone's health needs, starting today with the COVID-19 pandemic? We cannot wait for the next emergency.

We declare no competing interests. labour markets, and insufficient social protection mechanisms.

LMICs have nonetheless contributed substantially to the research on COVID-19 vaccines: of 199 country locations for 145 registered trials for the seven vaccines currently recommended by WHO, 2% were in low-income, 9% in lower-middle-income, 28% in upper-middle-income, and 62% in high-income countries (appendix). The considerable share of country locations in LMICs (39%) stands in stark contrast to the fragile access to vaccines in these regions. As of July, 2021, the share of the population that had received at least one dose of a COVID-19 vaccine was 1% in low-income, 8% in lowermiddle-income, and 19% in uppermiddle-income countries. 3 By September, 2021, the share had increased in lower-middle-income and upper-middle-income countries, but the pace has been painstakingly slow, and low-income countries have barely made any progress. 4 It is unacceptable that COVID-19 vaccine access in LMICs is based on voluntary international initiatives (eg, COVAX) or donations alone. Instead, the aforementioned ethical principle should be translated into binding legal mechanisms obliging pharmaceut ical companies to guarantee access to the fruits of medical research for vulnerable populations who participated in human experiments.

We declare no competing interests. Ezekiel Emanuel and colleagues 1 emphasise the eth ical obligations of pharmaceutical companies to combat the COVID-19 pandemic on the basis of four ethical principles: optimising vac cine production; fair distribution; sustainability; and accountability. We here add a fifth principle that arises from ethical considerations enshrined in the Helsinki Declaration, which requires that vulnerable groups participating in medical research benefit from resulting interventions. 2 Populations in low-income and middle-income countries (LMICs) can be considered particularly vulnerable during the COVID-19 pandemic due to weak health systems, few possibilities to self-isolate in man ual and informal

More than half of all vaccines have been distributed through such deals. The partially bilateral approach we endorse changes this state of affairs and enhances distribution of vaccines to LMICs that are suffering the greatest COVID-19-related harms.

Bozorgmehr and Jahn urge the prioritisation of countries that hosted vaccine trials. This is a backward-looking principle. If implemented, it would impede timely access to vaccines in many countries that are suffering from COVID-19, costing lives. We endorse a forward-looking principle-helping the countries suffering most from COVID-19. According to Bozorgmehr and Jahn's list, no mRNA vaccines were tested in lower-middle-income or low-income countries. Indeed, they list only a few lower-middle-income countries that hosted any vaccine trials, and only one low-income country (Mozambique). Preferentially allocating vaccines to countries that hosted trials favours those with research infrastructure, rather than those facing the worst burdens from COVID-19. That is not ethically defensible.

Bozorgmehr and Jahn also call for legally binding mechanisms to ensure access to COVID-19 vaccines. Our approach specifically emphasises companies' moral duties. 

Would exempting COVID-19 vaccines from intellectual property rights improve global access and equity?

Producing a vaccine requires more than a patent

Tracking global COVID-19 vaccine equity

Tracking global COVID-19 vaccine equity: an update

We thank Felipe de Carvalho Borges da Fonseca and colleagues, and Kayvan Bozorgmehr and Rosa Jahn for their comments on our Viewpoint. 1 We agree with de Carvalho Borges da Fonseca and colleagues about the need for "a more equitable, sustainable, and accountable medical innovation system". Whether waiving patent rights will meaningfully improve access to COVID-19 vaccines for lowincome and middle-income countries (LMICs), particularly in the short term, is an empirical matter. There is wide agreement that intellectual property (IP) for mRNA vaccines is not a primary barrier to vaccinating the world; 2,3 vaccine production, distribution, and administration are the rate-limiting steps.Sustainability is not about preserving the status quo, pharmaceutical companies, or current profits. What is important is the outcome: effectively addressing global health threats. We need to motivate innovative scientists and companies with the right research, development, and manufacturing capacity to put aside other projects and focus on a future pandemic or other health emergency. Uncoordinated efforts to waive IP rights without creating substitute incentives, or voluntary programmes that fail to attract participants, will not mobilise a vigorous response to either this or the next pandemic. Sustainability cannot be ignored. It concerns the ability of health systems to save lives in the future. Thus, sustainability is a moral imperative comparable to that of saving lives today.Most pharmaceutical companies are pursuing bilateral vaccine deals. 

The call for multi-level action for the promotion of participation of people living with disabilities (PLWD) in physical activity by Kathleen Martin Ginis and colleagues 1 underscores the lack of structural opportunities for participation. Health-care workers might provide long-term interventions to PLWD in and throughout life-course stages,